Topotecan-based Therapy

Topotecan-Based Therapy is a chemotherapeutic regimen classified under systemic cancer treatment that specifically incorporates the topoisomerase I inhibitor topotecan as the primary cytotoxic agent for targeting malignant cells in bone sarcoma.

832

Publications

46.6K

Citations

4.8K

Authors

1.3K

Institutions

Publications per year

2017–2026

112

Authors

4.8K

  1. CF
    Clinton F. Stewart

    St. Jude Children's Research Hospital, United States

    30 publications · 1.9K citations

    24

    h-index

  2. EK
    Eric K. Rowinsky

    The University of Texas at San Antonio Health Science Center, United States

    18 publications · 1.4K citations

    16

    h-index

  3. JV
    Jaap Verweij

    Rotterdam University of Applied Sciences, Netherlands

    17 publications · 1.4K citations

    15

    h-index

  4. SH
    Scott H. Kaufmann

    Mayo Clinic, United States

    14 publications · 1.5K citations

    14

    h-index

  5. JV
    Joachim von Pawel

    Asklepios Fachkliniken München-Gauting, Germany

    16 publications · 2.5K citations

    14

    h-index

1–5 of 4.8K

Venues

  1. Journal of Clinical Oncology

    92 publications · 13.4K citations

    59

    h-index

  2. PubMed

    Repository · 82 publications · 5.1K citations

    39

    h-index

  3. Gynecologic Oncology

    58 publications · 2.3K citations

    29

    h-index

  4. Annals of Oncology

    27 publications · 1.7K citations

    21

    h-index

  5. Cancer

    24 publications · 974 citations

    20

    h-index

1–5